User:Mr. Ibrahem/Mosunetuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD20, CD3 (bispecific) |
| Clinical data | |
| Trade names | Lunsumio |
| Synonyms | BTCT4465A, RG7828, mosunetuzumab-axgb |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Gradual injection into a vein[1] |
| Drug class | Antineoplastic |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6515H10031N1725O2025S43 |
| Molar mass | 146,301.54 g·mol−1 |
Mosunetuzumab, sold under the brand name Lunsumio, is a medication used to treat follicular lymphoma.[1] Specifically it is used after other medications have failed.[1] It is given by gradual injection into a vein.[1]
Common side effects (≥20%) include cytokine release syndrome, fever, and headache.[2] Other side effects may include immune effector cell-associated neurotoxicity syndrome (ICANS) and infections.[1] Common laboratory abnormalities include decreased low neutrophils, low phosphate, high glucose, low lymphocytes, increased uric acid, low white blood cells, low hemoglobin, and low platelets.[2][1] Use in pregnancy may harm the baby.[1] It is a monoclonal antibody specifically a bispecific CD20-directed CD3 T-cell engager.[1][2]
Mosunetuzumab was approved for medical use in Europe and the United States in 2022.[2][1] It costs about 180,000 USD for the course of treatment in the United States as of 2023.[4]
References
change- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Lunsumio- mosunetuzumab concentrate". DailyMed. 22 December 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Lunsumio EPAR". European Medicines Agency (EMA). 13 April 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma". U.S. Food and Drug Administration (FDA). 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023.
This article incorporates text from this source, which is in the public domain.
- ↑ "U.S. FDA approves Roche's lymphoma therapy". Reuters. 23 December 2022. Archived from the original on 4 January 2023. Retrieved 9 April 2023.
